Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Enfortumab vedotin in urothelial cancer

Jonathan Rosenberg • 4 Jun 2021
ASCO 2021
Genitourinary Cancer Urothelial Carcinoma Antibodies Cisplatin Enfortumab vedotin Gemcitabine Pembrolizumab
EV-103 EV-301

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the Phase Ib EV-103 trial (NCT03288545) assessing enfortumab vedotin in combination with other therapies in urothelial cancer (UC), and the Phase III EV-301 trial (NCT03474107) assessing enfortumab vedotin versus chemotherapy in UC. Despite a small cohort of 45 patients, the overall survival was reached in the EV-103 trial, and an additional existing cohort will evaluate the contribution of pembrolizumab. The EV-301 aims to investigate whether enfortumab vedotin can replace chemotherapy as first line therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting

More from Jonathan Rosenberg

The future of antibody-drug conjugates in urothelial carcinoma
1:39
The future of antibody-drug conjugates in urothelial carcinoma
Jonathan Rosenberg • 16 Sep 2024
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
1:35
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
Jonathan Rosenberg • 16 Sep 2024
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
Jonathan Rosenberg • 16 Sep 2024
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
1:30
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
Jonathan Rosenberg • 16 Sep 2024

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals